Previous Next

CURRENT ISSUE

№3' 2020

DERMATOVENEREOLOGY

International Medical Journal, Vol. 26., Iss. 3, 2020, P. 67−71.


DOI (https://doi.org/10.37436/2308-5274-2020-3-13)

COMPARATIVE ASSESSMENT OF β-DEFENSIN LEVELS IN PATIENTS WITH CHRONIC ECZEMA OF VARYING SEVERITY


Bolotna L. A., Lysenko K. I.

Kharkiv Medical Academy of Postgraduate Education, Ukraine

The infectious nature of the process in microbial eczema or complications of bacterial infection of true eczema indicates an impairment in the immune system, especially innate immunity. Primary pathogen receptors, the complement system, phagocytosis, interferons, and endogenous antibiotic peptides play a crucial role in the body's innate defense. The first line of defense is provided by antimicrobial peptides, which are non−specific factors of humoral immunity, and have endotoxin−neutralizing and immune modulatory activity, as well as act against a wide range of microorganisms. One of them is defensins, which are cationic amphipathic peptides with a length of 30 to 42 amino acids with a three−stranded β−plate structure containing three disulfide bonds. The main producers of human β−defensins (Human Beta Defensin) are various epithelial cells, including keratinocytes. Defensins have antibacterial, antiviral, antifungal and antiparasitic effects. β−defensins are active against gram−positive and gram−negative bacteria, in addition, they exhibit anti−yeast activity. In patients, the severity of dermatosis was determined based on the calculation of EASI (Eczema Area Severity Index), the content of Human Beta Defensin was done with enzyme−linked immunosorbent assay, in the serum of patients with chronic eczema, it was increased 15.9 times compared to the control group. Quantitative levels of Human Beta Defensin 2 have been shown to be closely related to the disease severity. The content of Human Beta Defensin 2 in the serum of patients with chronic eczema may be a marker of the dermatosis severity.

Key words: chronic eczema, true and microbial eczema, pathogenesis, β−defensin, severity.


REFERENCES


1. Aizyatulov R. F. Patogeneticheskie aspekty i kompleksnaya terapiya razlichnykh klinicheskikh form ekzemy // Klіn. іmunol., alergol., іnfektol. 2015. № 8 (87). S. 14−20.

2. Kliniko−immunologicheskie kharakteristiki nummulyarnoi ekzemy / V. Yu. Udzhukhu i dr. // Vestn. RGMU. 2018. № 1. S. 56−59.

3. Khronicheskaya istinnaya ekzema. Poisk terapii tyazhelykh form / V. V. Starostenko, O. A. Sidorenko, L. P. Sizyakina, E. E. Sidorenko // Med. vestn. Yuga Rossii. 2019. № 10 (1). S. 72−78.

4. Silvestre J. F. About the Need and the Future of Eczema Units // Actas Dermosifiliogr. 2018. Vol. 109, № 6. P. 465−467. doi: 10.101 10.1016/j.ad.2018.06.001

5. Bardova E. A. Ekzema v praktike semeinogo vracha: klinicheskie formy, differentsial'naya diagnostika, lechenie // Klіn. іmunol., alergol., іnfektol. 2013. № 1. S. 112−116.

6. Fu T. Eczema and sensitization to common allergens in the United States: a multiethnic, population−based study // Pediatr. Dermatol. 2014. Vol. 31, № 1. R. 21−26.

7. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids / R. A. Cortesi et al. // Contact Dermatit. 2014. Vol. 3, № 70. R. 158−168. doi: https://doi.org/10.1111/cod.12130

8. Sovremennye osobennosti kliniki, diagnostiki i terapii bol'nykh ekzemoi / L. A. Yusupova i dr. // Lech. vrach. 2018. № 6. S. 85−87.

9. Śpiewak R., Kordus K. The classification and definitions of diseases from the spectrum of eczema // Int. Rev. Allergol. Clin. Immunol. Family Med. 2012. Vol. 18, № 4. P. 210−221.

10. Aleksandruk O. D., Tkach V. Є. Diskusіinі pitannya klasifіkatsії ekzemi u suchasnіi dermatologії // Dermatovenerologiya. Kosmetologiya. Seksopatologiya. 2013. № 1−4. S. 214−219.

11. Denisova Ya. E. Sovremennye predstavleniya o molekulyarno−geneticheskikh mekhanizmakh vozniknoveniya istinnoi ekzemy // Nauchnye vedomosti: seriya "Meditsina. Farmatsiya". 2013. № 18 (161). S. 5−10.

12. Immunologicheskaya kontseptsiya razvitiya mikrobnoi ekzemy / N. A. Abdrakhimova i dr. // Med. vestn. Bashkortostana. 2014. № 9 (1). S. 109−118.

13. Kasikhina E. I., Glazko I. I., Ryabchikova M. D. Problemy mikst−infektsii: puti resheniya i osobennosti patogeneza // Klin. dermatol. venerol. 2014. № 12 (4). S. 56−60.

14. Colonization and infection of the skin by S. aureus: immune system evasion and the response to cationic antimicrobial peptides / S. Ryu et al. // Int. J. Mol. Sci. 2014. Vol. 15. P. 8753−8772. doi: https://doi.org/10.3390/ijms15058753

15. Diagnosticheskoe znachenie narushenii v sisteme vrozhdennogo immuniteta pri mikrobnoi ekzeme / E. L. Chalaya i dr. // Ros. zhurn. kozhn. ven. bolezn. 2016. № 19 (2). S. 122−123.

16. Friends or foes? Host defense (antimicrobial) peptides and proteins in human skin diseases / F. Niyonsaba, C. Kiatsurayanon, P. Chieosilapatham, H. Ogawa // Exp. Dermatol. 2017. Vol. 26. P. 989−998. doi: 10.1111/exd.13314

17. Expression and function of host defense peptides at inflammation sites / S. V. Prasad et al. // Int. J. Mol. Sci. 2020. Vol. 21, № 104. doi:10.3390/ijms2101010436−24

18. Antimikrobnye peptidy v norme i pri patologiyakh (obzor) / M. V. Konovalova, A. A. Zubareva, G. V. Lutsenko, E. V. Svirshchevskaya // Prikl. biokhim. mikrobiol. 2018. № 3. S. 236−240. doi: https://doi.org/10.7868/s0555109918030029

19. Fruitwala S., El−Naccache D. W., Chang T. E. Multifaceted immune functions of human defensins and underlying mechanisms // Semin. Cell. Dev. Biol. 2019. Vol. 88. P. 163−172. doi: https://doi.org/10.1016/j.semcdb.2018.02.023

20. Cherill R., Graeber M., Hanifin J. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis // J. Eur. Acad. Dermatol. Venereol. 1998. Vol. 11 (suppl. 2). P. 48−54. doi: https://doi.org/10.1016/s0926−9959(98)95291−6

21. Karakaeva A. V., Utts S. R. Rol' narushenii epidermal'nogo bar'era v patogeneze ekzemy (obzor) // Saratovsk. nauchn.−med. zhurn. 2014. № 10 (3). S. 525−530.

22. Takahashi T., Gallo R. L. The critical and multifunctional roles of antimicrobial peptides in dermatology // Dermatol. Clin. 2017. Vol. 35. R. 39−50. doi: 10.1016/j.det.2016.07.006

23. Sun L., W. Liu, Zhang L.−J. The role of Toll−like receptors in skin host defense, psoriasis, and atopic dermatitis // Hindawi J. of Immunology Research. 2019. Article ID 1824624, 13 p. doi: org/10.1155/2019/1824624

24. Marcinkiewicz M., Majewski S. The role of antimicrobial peptides in chronic inflammatory skin diseases // Adv. Dermatol. Allergol. 2016. Vol. XXXIII. R. 6−12. doi: 10.5114/pdia.2015.48066

Go on Top